Raafet A.
- Country
- France
- Department
- Service d'oncologie medicale
Research Overview
- Phase III Trial of BNT327 plus Combination Chemotherapy versus Placebo plus Chemotherapy in Patients with Previously Untreated Metastatic or Locally Recurrent Triple-Negative Breast Cancer
- A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
- A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease
Data & Insights
Has run more than one trial at 214 of 457 partner sites.
Specializations
Oncology: Breast and Kidney Cancer
This investigator specializes in treating hormone receptor-positive metastatic breast cancer and advanced renal cell carcinoma. Their work involves evaluating innovative therapeutic combinations, particularly focusing on endocrine therapy approaches and immunotherapy treatments.
- ER+/HER2- Metastatic Breast Cancer Management
- Advanced Kidney Cancer Immunotherapy
- Circulating Tumor DNA Analysis
Their expertise extends to monitoring treatment responses using biomarker detection and implementing targeted therapeutic strategies.
Thoracic and Urological Oncology
The investigator has significant experience in treating non-small cell lung cancer and high-risk muscle-invasive bladder cancer. Their research encompasses both early-stage and advanced disease states, with particular attention to immunotherapy applications.
- Advanced NSCLC Treatment Strategies
- Bladder Cancer Adjuvant Therapy
- Immunotherapy Combinations
Their work integrates molecular diagnostics and targeted therapies in thoracic and urological cancers.
Gynecologic Oncology
The investigator focuses on treating advanced endometrial cancer, with particular expertise in managing cases with specific molecular characteristics. Their research includes evaluation of novel therapeutic approaches for patients with MMR-deficient tumors.
- MMR-Deficient Endometrial Cancer
- Advanced/Metastatic Disease Management
- Molecular-Based Treatment Selection
Their approach incorporates precision medicine principles in gynecologic cancer treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.